Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI As Preferred Category 1 Regimen For First-Line Treatment Of Cancer Of The Nasopharynx
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI